REVIEW ARTICLE

Impact of Obesity on Response to Biologic Therapies in Patients with Inflammatory Bowel Diseases

Mehak Bassi[1] · Siddharth Singh[2,3]

Abstract

Approximately 20–40% of patients with inflammatory bowel disease (IBD) are obese. Obesity is associated with inferior outcomes in patients with IBD, with lower rates of achieving remission, poor quality of life, and higher burden of unplanned healthcare utilization. Multiple cohort studies in patients with immune-mediated inflammatory diseases, including IBD, treated with biologic agents like tumor necrosis factor-α antagonists have suggested that obesity is associated with inferior response to biologic therapy. This may be related to the negative impact of obesity on the pharmacokinetics of biologic agents. Pharmacokinetic studies of multiple biologic agents have demonstrated that high body weight is associated with more rapid clearance and a higher volume of distribution of biologic agents, which leads to low trough concentrations. Randomized trials in patients with psoriasis and psoriatic arthritis treated with biologic agents suggest that diet- or lifestyle-induced weight loss is associated with improved response to therapy. This provides an opportunity to explore intentional weight loss as adjunctive therapy in obese patients with IBD. However, diet and lifestyle interventions for weight loss are hard to implement in patients with IBD; hence, long-term therapy with weight-loss agents (such as with phentermine–topiramate, naltrexone–bupropion) is attractive as adjunctive therapy in obese patients with IBD.

Key Points

Approximately one-third of patients with inflammatory bowel disease (IBD) are obese, which negatively impacts disease course.

Obesity leads to more rapid clearance and low trough concentrations of biologic agents in patients with IBD.

Obesity is associated with decreased treatment responsiveness to biologics.

✉ Siddharth Singh
  sis040@ucsd.edu

1 Department of Medicine, Rutgers Biomedical and Health Sciences, Newark, NJ, USA

2 Division of Gastroenterology, Department of Medicine, University of California San Diego, ACTRI 1W501, 9452 Medical Center Dr., La Jolla, CA 92093, USA

3 Division of Biomedical Informatics, Department of Medicine, University of California San Diego, La Jolla, CA, USA

1 Introduction

The worldwide prevalence of obesity is rising; globally, approximately 39% of adults are classified as overweight and 13% as obese [1]. An estimated 35% of the United States population is obese, leading to rising healthcare expenditure [2, 3]. Rates of inflammatory bowel disease (IBD) are rising in parallel [4]. Obesity is an environmental exposure that has been implicated in these epidemiologic trends in IBD [5]. Obesity, which is linked to rising rates of immune-mediated inflammatory diseases like rheumatoid arthritis and psoriasis, has also been implicated in contributing to an increased risk of developing Crohn's disease (CD) [6]. In a pooled analysis of five prospective cohort studies with 601,009 participants, Chan and colleagues observed that obesity, based on body mass index (BMI) ≥ 30 mg/kg^2, is associated with a 34% higher risk of developing CD, compared with normal BMI; each 5-kg/m^2 increase in BMI was associated with a 16% higher risk of developing CD [7]. It is estimated that 15–35% of patients with IBD are obese, and 20–40% may be overweight [8]. Obesity has also been linked to higher disease activity and poorer quality of life in patients with IBD. In cohort studies, obese patients with IBD were more likely to relapse and have difficult to treat disease, leading to higher

△ Adis

rates of hospitalization, compared with non-obese patients [8–11]. Besides having a direct impact on the natural history of IBD, obesity may also negatively impact treatment response and disease outcomes in patients with IBD [8, 12].

The management of IBD, particularly of severe disease, involves the use of biologic agents, monoclonal antibodies (mAbs) such as tumor necrosis factor-α (TNFα) antagonists (infliximab, adalimumab, certolizumab pegol, and golimumab), interleukin-23 (IL-23) antagonists (ustekinumab), and lymphocyte trafficking inhibitors (vedolizumab) [13]. These drugs can effectively control the disease in 40–60% of patients, but the response between individuals varies greatly. In this review, we will examine whether obesity is associated with the effectiveness and safety of biologics in patients with IBD, and whether intentional weight loss in obese patients can modify this association.

2 Impact of Obesity on Pharmacokinetics and Pharmacodynamics of Biologic Agents

Biologic agents exert their pharmacologic effect when adequate drug concentrations are achieved at the drug's site of action. Inter- and intra-individual differences in bioavailability and pharmacokinetics may contribute to variability in treatment response. Several factors modify the pharmacokinetics of large mAbs and influence effectiveness [14]. Besides hypoalbuminemia, elevated inflammatory markers, anti-drug antibodies, and co-administration of immunosuppressive therapy, obesity has been a consistent factor that is associated with accelerated drug clearance and increased central volume of distribution, leading to unfavorable pharmacokinetics and low drug concentration at the site of action [8]. In a population pharmacokinetic study of intravenous vedolizumab, albumin and body weight were identified as predictors of clearance of vedolizumab, with a clinically meaningful impact observed at extremes of values [15]. This negative impact of body weight on drug clearance is seen regardless of whether fixed-dose or weight-based dosing regimens are used [16]. However, the magnitude of impact may vary by type of biologic, with a higher impact seen with TNFα antagonists like infliximab and adalimumab, and may be less pronounced with vedolizumab and ustekinumab. Table 1 summarizes findings from key studies on the impact of weight on the pharmacokinetics of different biologic agents.

Additionally, obesity, particularly visceral fat, independently contributes to the higher systemic inflammatory burden, which may modify treatment effectiveness.[17] Adipokines like resistin and leptin are proinflammatory [18]. White adipose tissue also synthesizes different proinflammatory cytokines such as TNFα, IL-1β, and IL-18 and other adipocytokines that can cause gut inflammation. Compared with lean individuals, obesity causes elevation of TNFα levels secreted by the fat tissue, causing increased pathogenesis of several inflammatory conditions and a direct effect on trough level of anti-TNF agents.

3 Impact of Obesity on Treatment Effectiveness of Biologic Agents

Given this potential association between obesity and IBD disease activity, multiple studies have sought to examine how obesity may impact response to biologics in patients with IBD. Some consistent findings stand out. First, patients with obesity are more likely to require higher doses of the medication, through dose escalation [9]. In a prospective cohort of adalimumab-treated patients with CD, Bultman et al. [19] observed that over one-third of patients required adalimumab dose escalation (to every week dosing from every 2 weeks) within 5 months of starting therapy; higher BMI was the only independent factor predictive of dose escalation. In another retrospective study, Bhalme et al. observed that obese patients treated with adalimumab were almost two times more likely to require dose escalation compared with patients with normal BMI [20]. Interestingly, morbidly obese patients may not receive their optimal dosing for weight-based therapies, frequently being underdosed. Seminerio and colleagues observed that the average dose of infliximab in patients with class III obesity was ~ 4 mg/kg, compared to 7.9 mg/kg in normal BMI patients and 6.4 mg/kg body weight in overweight patients [21].

Second, obesity may impact treatment response to biologics independent of drug exposure. Kurnool et al. [22] observed that each unit increase in BMI was associated with a 4% increase in risk of treatment failure, 8% increase in risk of surgery or hospitalization, and 6% lower odds of achieving endoscopic remission in a cohort of 160 biologic-treated patients with ulcerative colitis (UC), with comparable effects seen with fixed-dose therapies and weight-based agents. In another study of infliximab-treated patients with IBD, obese patients were three to nine times more likely to have an IBD flare and require biologic dose-escalation than normal-weight patients [23]. Each 1-kg/m^2 increase in BMI was associated with a 6% higher risk of CD flare (hazard ratio [HR] 1.06; 95% confidence interval [CI] 1.02–1.11) and 30% higher risk of UC flare (HR 1.30; 95% CI 1.07–1.58). Secondary analyses of clinical trials, however, have not confirmed these observations. In a secondary analysis of clinical trials of infliximab in patients with UC, obesity was not associated with a risk of achieving remission or mucosal healing over the short term [24]. Similarly, in a post hoc analysis of 254 patients treated with ustekinumab in IM-UNITI, Wong and colleagues observed that at week 44,

Table 1 Impact of obesity on PK of different biologics used for the management of IBD

Drug	Study design	Study objectives	Conclusion
Adalimumab [45]	Prospective, observational, multicenter study	Characterize the PK of adalimumab and identify clinically significant determinants of adalimumab clearance	High lean body weight and positive antibodies to adalimumab were important predictors of adalimumab clearance
Golimumab [46]	3 phase II/III studies of golimumab in patients with UC	Characterize the PK and exposure-response relationship of golimumab in patients with UC	Clearance of golimumab was explained by a 2-compartment model with first-order absorption and elimination
			Clearance of golimumab increased when body weight increased from 25th percentile to 75th percentile
Vedolizumab [47]	5 clinical studies in patients, including 1 phase I study in healthy volunteers, 1 phase II UC study, and 3 phase III UC/CD studies	Characterize the PK of vedolizumab and identify clinically significant determinants of vedolizumab clearance	Clearance of vedolizumab was explained by a 2-compartment model with parallel linear and nonlinear elimination
			Extreme values of body weight (> 120 kg) and albumin are clinically significant predictors of vedolizumab clearance
Ustekinumab [48]	2 phase III, randomized, double-blind, placebo-controlled, parallel-group, multicenter studies	Characterize the PK and exposure-response relationship of ustekinumab, in the treatment of moderately to severely active UC	Observed serum concentration–time data of ustekinumab can be explained by a 2-compartment linear PK model with first-order absorption and first-order elimination
			Besides albumin, sex, and antibodies to ustekinumab, body weight is a covariate that influences ustekinumab PK, but the magnitude of this effect is likely not clinically relevant
Risankizumab [49]	Phase I and phase II study in patients with psoriasis vs. phase II study in patients with CD	Characterize PK of risankizumab and evaluate covariates that affect exposure, in patients with psoriasis and CD	Clearance of risankizumab was explained by a 2-compartment model with first-order absorption and elimination
			Body weight and baseline albumin are significant covariates that explain variability in risankizumab exposure

CD Crohn's disease, *IBD* inflammatory bowel disease, *PK* pharmacokinetics, *UC* ulcerative colitis

rates of clinical remission did not differ among those whose BMI was underweight (67.9%; 19 of 28 patients), normal (51.3%; 60 of 117), overweight (45.1%; 32 of 71), or obese (55.3%; 21 of 38) ($p = 0.89$) [25].

While there are limited data in IBD, similar observations have been made in biologic-treated patients with other autoimmune diseases. In a prospective cohort of 89 infliximab-treated patients with rheumatoid arthritis, obese patients had lower rates of clinical response compared with non-obese patients. This effect persisted after adjustment for baseline disease activity and other prognostic factors (BMI > 30 kg/m^2 vs. 20–30 kg/m^2 vs. < 20 kg/m^2: 50% vs. 75% vs. 84%) [26]. Gremese et al. similarly observed that, at 12 months, rates of clinical remission were lowest in obese patients, compared with overweight or normal BMI individuals (15% vs. 30% vs. 33%) [27]. Likewise, in 557 patients with psoriatic arthritis (35% obese), the likelihood of achieving sustained minimal disease activity was lowest in obese (odds ratio [OR] 0.52; 95% CI 0.40–0.67) and overweight (OR 0.65; 95% CI 0.50–0.85) patients, as compared to patients with normal BMI [28]. In a systematic review of 54 cohorts including 19,372 TNFα antagonist-treated patients with immune-mediated inflammatory diseases (23% obese), we observed that patients with obesity had 60% higher odds of failing therapy (OR 1.60; 95% CI 1.39–1.83), with a dose–response relationship; each 1-kg/m^2 increase in BMI was associated with 6.5% higher odds of treatment failure [12].

Visceral adiposity, on top of overall obesity, may also influence response to biologics. In a retrospective cohort study of 176 TNFα antagonist-treated patients with IBD, Gu and colleagues observed that, compared with patients with a visceral fat index < 0.33, patients with a visceral fat index ≥ 0.67 had higher odds of surgery at 6 and 12 months [29]. Post hoc analysis suggested visceral adipose tissue volume may affect drug pharmacokinetics. Similarly, Lim and colleagues observed that higher visceral adipose tissue area was inversely associated with infliximab trough concentrations and a higher risk of secondary loss of response to adalimumab [30].

4 Impact of Obesity on Treatment Safety of Biologic Agents

Obesity has been consistently associated with an increased risk of surgical site infections [31]. Mechanistically, visceral adipose tissue is metabolically active and can modify the immune response through pro- and anti-inflammatory adipokines, cytokines, and chemokines, which predisposes to infection. However, whether obesity modifies the risk of infections in patients with IBD, particularly those being treated with immunosuppressive agents, has not been

well-studied. In a cohort study of approximately 6000 biologic-treated patients with IBD (8.8% obese), we observed that obesity was not associated with risk of serious infections [32]. On univariate analysis, risk of serious infections was comparable in obese versus non-obese patients (8.8% vs. 8.5%). On Cox proportional hazard analysis, after adjusting for key covariates, obesity was not associated with an increased risk of serious infections (HR 0.74; 95% CI 0.55–1.01).

5 Would Intentional Weight Loss Improve Response to Biologic Agents in Patients with IBD?

If obesity decreases the effectiveness of biologics, a natural question is whether intentional weight loss may make biologics more effective. Unfortunately, this is a key evidence gap. There are no trials examining intentional weight loss in obese patients with IBD. Trials examining diet and/or lifestyle-related weight loss suggest superior outcomes with weight loss in patients with other immune-mediated inflammatory diseases [8]. In a meta-analysis of patients with overweight or obesity and psoriasis, patients receiving weight-loss interventions were almost three times more likely to achieve significant clinical improvement, compared with standard of care [33]. Even 5% weight loss over baseline may be sufficient for patients to experience benefits of weight loss. Di Minno et al., compared low-calorie or free-managed diet for weight loss in a 6-month randomized trial of 126 patients with psoriatic arthritis starting TNFα antagonist therapy. They observed that patients randomized to the low-calorie diet noticed greater reduction in pain and inflammation, and were significantly more likely to achieve remission (low-calorie diet vs. free-range diet: 43% vs. 35%) [34]. Interestingly, it was not the diet itself that resulted in benefit; patients who achieved greater weight loss regardless of specific intervention were significantly more likely to achieve favorable outcomes. Overall, 60%, 45%, and 23% of patients with > 10% weight loss, 5–10% weight loss, and < 5% weight loss achieved remission, respectively. Patients with > 5% weight loss were 4.2 times more likely to achieve remission compared with those who experienced < 5% weight loss (OR 4.20; 95% CI 1.82–9.66).

Whether patients with obesity and IBD would experience similar benefits with weight loss is speculative. Case series have suggested that bariatric surgery may be performed highly selectively in morbidly obese patients with IBD, with observed improvement in disease activity after weight loss [35]. In a case–control study involving 88 bariatric procedures (73 with sleeve gastrectomy) in 85 obese patients with IBD matched 1:2 on age, sex, BMI, hospital of surgery, and type of bariatric surgery with obese patients with IBD

who underwent bariatric surgery, patients with IBD did not have any increase in the risk of perioperative complications, post-operative nutritional deficiencies, or effectiveness in weight loss, over 2 years [36]. However, long-term consequences of major restrictive and malabsorptive procedures in patients with IBD are poorly understood. In a population-based cohort study, bariatric surgery was associated with an increased risk of new-onset CD, but not UC [37]. Hence, risks and benefits of bariatric surgery should be very carefully weighed in selected patients with IBD. It is unclear whether minimally invasive or non-invasive approaches to weight loss may offer benefit.

Dietary interventions carry the lowest risk of adverse events, but adherence to a specific diet is limited. Intensive sustained lifestyle interventions are challenging in patients with IBD, especially those with active disease. They offer only small average weight loss with commercial weight-loss programs. That lost weight is frequently regained over time [38]. Weight loss achieved through pharmacologic or endoscopic bariatric interventions may achieve the same effect on outcomes in autoimmune diseases, but has not been studied. These medications typically result in 45–77% of patients achieving > 5% weight loss over placebo, with a magnitude of average excess weight loss (over placebo) ranging from 2.6 kg (with orlistat) to 8.8 kg (phentermine–topiramate) [39]. Orlistat, which works by inhibiting gastric and pancreatic lipases, reducing absorption of monoaclglycerides and free fatty acids, may not be appropriate in patients with IBD, especially those with active small CD who may have chronic malabsorption syndrome [40]. Naltrexone and bupropion have been individually shown to induce weight loss through poorly understood central nervous system effects. The combination is believed to act in synergy to modulate the hypothalamic melanocortin system and the mesolimbic reward system to regulate both the intake of food and body weight [40]. Two small trials have suggested that low-dose naltrexone may induce clinical and endoscopic response in patients with CD; it is unclear whether this effect is mediated by weight loss [41]. Case reports and case series have also suggested that bupropion may decrease IBD-related inflammation, by decreasing TNFα; it has also been shown to decrease fatigue and aid in smoking cessation, which itself benefits CD [42, 43]. Phentermine–topiramate is a highly efficacious oral weight-loss agent, which acts centrally to suppress appetite and increase satiety [40]. Preclinical data supports an anti-inflammatory role of both topiramate and phentermine. Using a novel computational approach for drug repositioning, Dudley et al. [44] observed that gene expression profiles of topiramate were very similar to those of corticosteroids. Subsequent in vivo testing demonstrated that administration of topiramate for 7 days after trinitrobenzenesulfonic acid-induced colitis resulted in significant reduction in diarrhea and reduced pathologic inflammation. A phase 2 clinical trial of Food and Drug Administration (FDA)-approved weight-loss medication phentermine–topiramate in obese biologic-treated patients with UC is ongoing (NCT04721873).

6 Conclusion

In conclusion, the prevalence of obesity in patients with IBD is sizable, paralleling the general population, contrary to conventional beliefs that this patient population is malnourished. Obesity, in particular visceral adiposity, may promote intestinal inflammation. Based on pharmacokinetic data, obesity appears to promote rapid clearance of biologic agents, regardless of drug dose. This translates into the inferior response to biological therapy in patients with obesity. This provides an opportunity for using treatment directed towards obesity, either through lifestyle, pharmacologic, or endoscopic interventions, as adjunctive therapy in obese patients with IBD, though prospective, interventional studies are lacking.

Declarations

Conflicts of interest Mehak Bassi: None. Siddharth Singh: Research grants from AbbVie, Pfizer, and Janssen; Personal fees from Pfizer (for ad hoc grant review).

Ethics approval Not applicable.

Consent to participate Not applicable.

Consent for publication Not applicable.

Availability of data and materials This is a review of published literature, without generation of new data.

Code availability Not applicable.

Author contributions MB and SS were both involved in study concept and design, acquisition of data, analysis and interpretation, drafting and critical revision, and final approval of the manuscript.

References

1. Global Burden of Diseases Collaborators. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377:13–27.

2. Ward ZJ, Bleich SN, Cradock AL, et al. Projected US state-level prevalence of adult obesity and severe obesity. N Engl J Med. 2019;381:2440–50.

3. Finkelstein EA, Trogdon JG, Cohen JW, et al. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff (Millwood). 2009;28:w822–31.

4. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390:2769–78.

5. Ananthakrishnan AN, Kaplan GG, Ng SC. Changing global epidemiology of inflammatory bowel diseases: sustaining health care delivery into the 21st century. Clin Gastroenterol Hepatol. 2020;18:1252–60.

6. Versini M, Jeandel PY, Rosenthal E, et al. Obesity in autoimmune diseases: not a passive bystander. Autoimmun Rev. 2014;13:981–1000.

7. Chan SSM, Chen Y, Casey K, et al. Obesity is associated with increased risk of Crohn's disease, but not ulcerative colitis: a pooled analysis of five prospective cohort studies. Clin Gastroenterol Hepatol. 2021.

8. Singh S, Dulai PS, Zarrinpar A, et al. Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes. Nat Rev Gastroenterol Hepatol. 2017;14:110–21.

9. Singh S, Picardo S, Seow CH. Management of inflammatory bowel diseases in special populations: obese, old, or obstetric. Clin Gastroenterol Hepatol. 2020;18:1367–80.

10. Jain A, Nguyen NH, Proudfoot JA, et al. Impact of obesity on disease activity and patient-reported outcomes measurement information system (PROMIS) in inflammatory bowel diseases. Am J Gastroenterol. 2019;114:630–9.

11. Nguyen NH, Ohno-Machado L, Sandborn WJ, et al. Obesity is independently associated with higher annual burden and costs of hospitalization in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2019;17:709–18.

12. Singh S, Facciorusso A, Singh AG, et al. Obesity and response to anti-tumor necrosis factor-alpha agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis. PLoS ONE. 2018;13:e0195123.

13. Baumgart DC, Le Berre C. Newer biologic and small-molecule therapies for inflammatory bowel disease. N Engl J Med. 2021;385:1302–15.

14. Hemperly A, Sandborn WJ, Vande CN. Clinical pharmacology in adult and pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2018;24:2527–42.

15. Rosario M, Dirks NL, Milch C, et al. A review of the clinical pharmacokinetics, pharmacodynamics, and immunogenicity of vedolizumab. Clin Pharmacokinet. 2017;56:1287–301.

16. Vande Casteele N, Gils A. Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: adding value to current practice. J Clin Pharmacol. 2015;55(Suppl 3):S39-50.

17. Balistreri CR, Caruso C, Candore G. The role of adipose tissue and adipokines in obesity-related inflammatory diseases. Mediators Inflamm. 2010;2010:802078.

18. Kredel L, Batra A, Siegmund B. Role of fat and adipokines in intestinal inflammation. Curr Opin Gastroenterol. 2014;30:559–65.

19. Bultman E, de Haar C, van Liere-Baron A, et al. Predictors of dose escalation of adalimumab in a prospective cohort of Crohn's disease patients. Aliment Pharmacol Ther. 2012;35:335–41.

20. Bhalme M, Sharma A, Keld R, et al. Does weight-adjusted anti-tumour necrosis factor treatment favour obese patients with Crohn's disease? Eur J Gastroenterol Hepatol. 2013;25:543–9.

21. Seminerio JL, Koutroubakis IE, Ramos-Rivers C, et al. Impact of obesity on the management and clinical course of patients with inflammatory bowel disease. Inflamm Bowel Dis. 2015;21:2857–63.

22. Kurnool S, Nguyen NH, Proudfoot J, et al. High body mass index is associated with increased risk of treatment failure and surgery in biologic-treated patients with ulcerative colitis. Aliment Pharmacol Ther. 2018;47:1472–9.

23. Harper JW, Sinanan MN, Zisman TL. Increased body mass index is associated with earlier time to loss of response to infliximab in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:2118–24.

24. Singh S, Proudfoot J, Xu R, et al. Obesity and response to infliximab in patients with inflammatory bowel diseases: pooled analysis of individual participant data from clinical trials. Am J Gastroenterol. 2018;113:883–9.

25. Wong ECL, Marshall JK, Reinisch W, et al. Body Mass index does not impact clinical efficacy of Ustekinumab in Crohn's disease: a post hoc analysis of the IM-UNITI trial. Inflamm Bowel Dis. 2021;27:848–54.

26. Klaasen R, Wijbrandts CA, Gerlag DM, et al. Body mass index and clinical response to infliximab in rheumatoid arthritis. Arthritis Rheum. 2011;63:359–64.

27. Gremese E, Bernardi S, Bonazza S, et al. Body weight, gender and response to TNF-alpha blockers in axial spondyloarthritis. Rheumatol (UK). 2014;53:875–81.

28. Eder L, Thavaneswaran A, Chandran V, et al. Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. Ann Rheum Dis. 2015;74:813–7.

29. Gu P, Chhabra A, Chittajallu P, et al. Visceral adipose tissue volumetrics inform odds of treatment response and risk of subsequent surgery in ibd patients starting antitumor necrosis factor therapy. Inflamm Bowel Dis. 2021.

30. Lim Z, Welman CJ, Raymond W, et al. The effect of adiposity on anti-tumor necrosis factor-alpha levels and loss of response in crohn's disease patients. Clin Transl Gastroenterol. 2020;11:e00233.

31. Falagas ME, Kompoti M. Obesity and infection. Lancet Infect Dis. 2006;6:438–46.

32. Singh S, Heien HC, Sangaralingham L, et al. Obesity is not associated with an increased risk of serious infections in biologic-treated patients with inflammatory bowel diseases. Clin Transl Gastroenterol. 2021;12:e00380.

33. Upala S, Sanguankeo A. Effect of lifestyle weight loss intervention on disease severity in patients with psoriasis: a systematic review and meta-analysis. Int J Obes (Lond). 2015;39:1197–202.

34. Di Minno MND, Peluso R, Iervolino S, et al. Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor alpha blockers. Ann Rheum Dis. 2014;73:1157–62.

35. Garg R, Mohan BP, Ponnada S, et al. Safety and efficacy of bariatric surgery in inflammatory bowel disease patients: a systematic review and meta-analysis. Obes Surg. 2020;30:3872–83.

36. Reenaers C, de Roover A, Kohnen L, et al. Bariatric surgery in patients with inflammatory bowel disease: a case-control study from the GETAID. Inflamm Bowel Dis. 2021.

37. Allin KH, Jacobsen RK, Ungaro RC, et al. Bariatric surgery and risk of new-onset inflammatory bowel disease: a nationwide cohort study. J Crohns Colitis. 2021;15:1474–80.

38. Johnston BC, Kanters S, Bandayrel K, et al. Comparison of weight loss among named diet programs in overweight and obese adults: a meta-analysis. JAMA. 2014;312:923–33.

39. Khera R, Murad MH, Chandar AK, et al. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA. 2016;315:2424–34.

40. LeBlanc ES, Patnode CD, Webber EM, et al. Behavioral and pharmacotherapy weight loss interventions to prevent obesity-related morbidity and mortality in adults: updated evidence report and systematic review for the US preventive services task force. JAMA. 2018;320:1172–91.
41. Parker CE, Nguyen TM, Segal D, et al. Low dose naltrexone for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2018;4:CD010410.
42. Brustolim D, Ribeiro-dos-Santos R, Kast RE, et al. A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice. Int Immunopharmacol. 2006;6:903–7.
43. Kane S, Altschuler EL, Kast RE. Crohn's disease remission on bupropion. Gastroenterology. 2003;125:1290.
44. Dudley JT, Sirota M, Shenoy M, et al. Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med. 2011;3:96–176.
45. Vande Casteele N, Baert F, Bian S, et al. Subcutaneous absorption contributes to observed interindividual variability in adalimumab serum concentrations in Crohn's disease: a prospective multicentre study. J Crohns Colitis. 2019;13:1248–56.
46. Adedokun OJ, Xu Z, Liao S, et al. Population pharmacokinetics and exposure-response modeling of golimumab in adults with moderately to severely active ulcerative colitis. Clin Ther. 2020;42:157–74.
47. Rosario M, Dirks NL, Gastonguay MR, et al. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease. Aliment Pharmacol Ther. 2015;42:188–202.
48. Xu Y, Hu C, Chen Y, et al. Population pharmacokinetics and exposure-response modeling analyses of ustekinumab in adults with moderately to severely active ulcerative colitis. J Clin Pharmacol. 2020;60:889–902.
49. Suleiman AA, Khatri A, Minocha M, et al. Population pharmacokinetics of the interleukin-23 inhibitor risankizumab in subjects with psoriasis and Crohn's disease: analyses of phase I and II trials. Clin Pharmacokinet. 2019;58:375–87.